Nanotechnology Now - Press Release: "Nanogen Reports 2006 Fourth Quarter and Year-End Financial Results"

Home > Press > Nanogen Reports 2006 Fourth Quarter and Year-End Financial Results

Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, today reported its unaudited financial results for the quarter ended December 31, 2006.

Nanogen Reports 2006 Fourth Quarter and Year-End Financial Results

San Diego, CA | Posted on February 20th, 2007

Total revenues for the fourth quarter of 2006 nearly tripled to $8.7 million from $3.1 million in the same period in 2005, and increased by 16 percent from the $7.5 million recorded in the third quarter of 2006. Product revenues for the fourth quarter of 2006 were approximately $5.1 million, which represents a substantial increase from $1.2 million for the fourth quarter of 2005 and an increase of approximately 9 percent as compared to $4.7 million for the third quarter of 2006.

Costs and expenses, including cost of sales, increased by $5.5 million from $14.1 million in the fourth quarter of 2005, excluding the nonrecurring $59.0 million impairment of goodwill charge in that period, to $19.6 million in the fourth quarter of 2006. Expenses, including cost of sales and separation costs recorded in the fourth quarter, totaled $19.6 million in the fourth quarter of 2006 or relatively steady as compared to the $19.1 million in the previous quarter of 2006.

For the quarter ended December 31, 2006, Nanogen's net loss was $11.2 million or $0.17 per share, compared to a net loss of $69.7 million including the $59.0 million impairment of goodwill charge or $1.27 per share for the same quarter in 2005, and $11.8 million or $0.18 per share in the quarter ended September 30, 2006.

"We have steadily grown our revenues during each quarter of 2006 as a result of both acquisitions and organic growth," said Howard C. Birndorf, Nanogen's chairman of the board and CEO. "As expected, EBITDA improvement accelerated during the second half of 2006, and we will continue to focus on improving this performance measure."

Nanogen's consolidated cash, cash equivalents and short-term investments balance at the end of the fourth quarter of 2006 was approximately $25.2 million. The company has since issued an additional $7.5 million of stock to enhance its cash resources.

"Looking ahead, we expect to maintain solid double digit growth as we achieve milestones that include the submission of assays to the FDA for the NanoChip® 400, the expansion of our real-time business and the introduction of new easy to use rapid tests," said David Ludvigson, Nanogen's president and COO.

Financial Guidance for 2007:

Nanogen expects annual revenue growth to exceed fifty percent during 2007 as compared to 2006 and to continue improving modified EBITDA.

Modified EBITDA declined as expected in the fourth quarter. Management remains committed to continuing to improve this measure of performance in future quarters.

                                 Three months ended Three months ended
                                    December 31,      September 30,

                                        2006               2006
                                 ------------------ ------------------

                                    (Unaudited)        (Unaudited)
Net loss                                  $(11,238)          $(11,782)
Net interest                                   556                (32)
Provision for income taxes                      99                150
Add depreciation and
 amortization                                1,724              1,776
                                 ------------------ ------------------
EBITDA                                      (8,859)            (9,888)
Add stock-based compensation                 1,248              1,212
Add Jurilab net loss                         1,316              1,309
Add warrant valuation adjustment                (2)                10
                                 ------------------ ------------------
Modified EBITDA                            $(6,297)           $(7,357)
                                 ================== ==================

Management uses the non-GAAP modified EBITDA for financial guidance because management does not consider non-cash stock based compensation expense, minority-owned Jurilab's results of operations, or the non-cash warrant valuation adjustments in evaluating the performance of continuing operations of the company. Management focuses on cash management and the company's majority-owned rather than minority-owned subsidiaries as they are indicative of the success or failure of on-going business operations. Therefore, management calculates the modified EBITDA provided in this earnings release and the resulting financial guidance for 2007 to enable investors to analyze further and more consistently the period-to-period financial performance of our business operations. Management also uses non-GAAP measures in costs and expenses excluding non-recurring impairment of goodwill charge in order to provide investors with a fuller analysis of the period-to-period comparison of the company's financial performance. Management believes that by providing investors with these non-GAAP measures it gives the investor additional important information to enable them to assess, in a way management assesses, the company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies.

The financial results included in this press release are unaudited. The complete, audited financial statements of the company for the year ended December 31, 2006 will be included in Nanogen's Annual Report on Form 10-K to be filed with the SEC in March 2007.

Webcast of Conference Call

Nanogen management will host a conference call to discuss the fourth quarter 2006 results today at 4:30 p.m. Eastern (1:30 p.m. Pacific). Interested investors and others may participate in the conference call by dialing (877) 407-9205 for US/Canada participants and (201) 689-8054 for international participants.

Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on February 20, and can be accessed via telephone at (877) 660-6853 for US/Canada participants and (201) 612-7415 for international participants. The account number, 286, along with the conference ID, 231215, will be required to listen to the playback.

                            NANOGEN, INC.
                     CONSOLIDATED BALANCE SHEETS
           (in thousands, except par value and share data)

                                                  As of December 31,
                                                 ---------------------
                                                    2006       2005
                                                 ----------- ---------
                                                 (unaudited)
                     ASSETS
Current assets:
  Cash and cash equivalents                         $11,261    $6,194
  Short-term investments                             13,923    26,185
  Receivables, net                                   11,568     2,141
  Inventories, net                                    7,691     3,724
  Other current assets                                2,058     1,457
                                                 ----------- ---------
    Total current assets                             46,501    39,701

Property and equipment, net                           9,388     7,590
Acquired technology rights, net                      17,894     9,604
Restricted cash                                       5,131     1,794
Other assets, net                                     1,312     2,214
Goodwill                                             39,027    37,178
                                                 ----------- ---------
  Total assets                                     $119,253   $98,081
                                                 =========== =========


      LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Accounts payable and accrued liabilities          $13,396    $7,728
  Acquisition payable, secured by letter of
   credit                                             2,570         -
  Deferred revenue                                    3,376       535
  Short-term assigned royalty interests
   obligation                                         3,447         -
  Common stock warrants                                  11        86
  Current portion of debt obligations                 3,590       701
                                                 ----------- ---------
    Total current liabilities                        26,390     9,050

Debt obligations, less current portion                  535       643
Debt obligation variable interest entity              7,406     7,245
Sponsored research payable                            4,851     4,854
Long-term assigned royalty interests obligation      15,529         -
Other long-term liabilities                           2,304     1,794
                                                 ----------- ---------
    Total long-term liabilities                      30,625    14,536

Commitments and contingencies

Stockholders' equity:
  Convertible preferred stock, $0.001 par value,
   5,000,000 shares authorized at December 31,
   2006 and 2005; no shares issued and
   outstanding at December 31, 2006 and 2005             --        --
  Common stock, $0.001 par value, 135,000,000
   shares authorized at December 31, 2006 and
   2005, respectively; 67,883,670 and 54,794,648
   shares issued and outstanding at December 31,
   2006 and 2005, respectively                           68        55
  Additional paid-in capital                        429,971   396,297
  Accumulated other comprehensive loss               (1,458)     (189)
  Deferred compensation                                  --    (2,218)
  Capital deficit in consolidated variable
   interest entity, net                              (4,839)   (6,856)
  Accumulated deficit                              (360,733) (311,656)
  Treasury stock, at cost, 416,027 and 505,830
   shares at December 31, 2006 and 2005,
   respectively                                        (771)     (938)
                                                 ----------- ---------
  Total stockholders' equity                         62,238    74,495
                                                 ----------- ---------
  Total liabilities and stockholders' equity       $119,253   $98,081
                                                 =========== =========

                            NANOGEN, INC.
           CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                             (unaudited)
                (in thousands, except per share data)

                               Three Months Ended  Twelve Months Ended
                                   December 31,        December 31,
                               ------------------- -------------------
                                 2006      2005      2006      2005
                               --------- --------- --------- ---------
Revenues:
  Product sales                  $5,132    $1,196   $15,996    $4,544
  License fees and royalty
   income                         2,413     1,459     7,908     6,530
  Contracts and grants            1,139       407     2,948     1,470
                               --------- --------- --------- ---------
Total revenues                    8,684     3,062    26,852    12,544

Costs and expenses:
  Cost of product sales           3,542     1,445    13,290     4,518
  Research and development        6,628     6,427    25,683    22,033
  Selling, general and
   administrative                 8,652     5,875    33,385    23,578
  Impairment charge on
   goodwill                          --    59,000        --    59,000
  Impairment of acquired
   technology rights                 --        --        --       167
  Amortization of purchased
   intangible assets                827       393     2,987     1,571
                               --------- --------- --------- ---------
Total costs and expenses         19,649    73,140    75,345   110,867
                               --------- --------- --------- ---------

Loss from operations            (10,965)  (70,078)  (48,493)  (98,323)

Other income (expense):
  Interest income (expense),
   net                             (556)      266      (246)      864
  Other income (expense)            (73)       40      (716)      (78)
  Warrant valuation adjustment        2        80        74     1,026
  Gain on foreign currency
   transactions                     354        14       311        17
                               --------- --------- --------- ---------
Total other income (expense)       (273)      400      (577)    1,829
                               --------- --------- --------- ---------

Net loss                       $(11,238) $(69,678) $(49,070) $(96,494)
                               ========= ========= ========= =========

Net loss per share -- basic
 and diluted                     $(0.17)   $(1.27)   $(0.78)   $(1.95)
                               ========= ========= ========= =========

Number of shares used in
 computing net loss per share
 -- basic and diluted            67,968    54,689    63,221    49,585
                               ========= ========= ========= =========
*T

####
About Nanogen
 Nanogen's advanced technologies provide researchers, clinicians and physicians
 worldwide with improved methods and tools to predict, diagnose, and ultimately
 help treat disease. The company's products include real-time PCR reagents, the
 NanoChip(R)400 electronic microarray platform and a line of rapid,
 point-of-care diagnostic tests. Nanogen's ten years of pioneering research 
involving nanotechnology holds the promise of miniaturization and continues to
 be supported for its potential for diagnostic and biodefense applications. For
 additional information please visit Nanogen's website at http://www.nanogen.com .



 
Nanogen Forward-Looking Statement



 
This press release contains forward-looking statements that are subject to risks
 and uncertainties that could cause actual results to differ materially from 
those set forth in the forward-looking statements, including whether patents 
owned or licensed by Nanogen will be developed into products, whether the
 patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties 
discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and 
Exchange Commission. These forward-looking statements speak only as of the date
 hereof. Nanogen disclaims any intent or obligation to update these 
forward-looking statements. 

For more information, please click here
Contacts:
Suzanne Clancy, Ph.D.
Nanogen, Inc.
858-410-4688


Pam Lord
Porter Novelli Life Sciences
619-849-6003

Copyright © Nanogen
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
  
Bookmark:
 
  
  
  
  
  
  
  
  
  
  









Related News Press
Announcements

    Competition in the Quantum World May 20th, 2013

    Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013  May 20th, 2013

    Penn engineers' nanoantennas improve infrared sensing May 20th, 2013

    Researchers Perform Fastest Measurements Ever Made of Ion Channel Proteins  May 20th, 2013
Financial Reports

    Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013

    Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013

    Arrowhead Reports Fiscal 2013 Second Quarter Financial Results  - Conference Call Today at 4:30 p.m. Eastern Time   May 9th, 2013

    Arrowhead to Report Fiscal 2013 Second Quarter Financial Results - Conference Call Scheduled for Thursday, May 9, 2013 May 2nd, 2013